- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.10. | Azitra expands trial eligibility for ATR-04 skin rash treatment | 1 | Investing.com | ||
| 26.10. | Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin | 165 | PR Newswire | ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements... ► Artikel lesen | |
| 22.10. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10. | Azitra To Implement 1-for-10 Reverse Stock Split | 1 | RTTNews | ||
| AZITRA Aktie jetzt für 0€ handeln | |||||
| 16.10. | Azitra announces 1-for-10 reverse stock split | 1 | Seeking Alpha | ||
| 16.10. | Azitra announces 1-for-10 reverse stock split effective Oct. 26 | 1 | Investing.com | ||
| 16.10. | Azitra, Inc. Announces Reverse Stock Split | 2.804 | PR Newswire | Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026
BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR)... ► Artikel lesen | |
| 01.10. | Azitra, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.10. | Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance | 245 | PR Newswire | BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 08.09. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.08. | Azitra regains NYSE American listing compliance | 2 | Seeking Alpha | ||
| 21.08. | Azitra erfüllt wieder die Notierungsstandards der NYSE American | 1 | Investing.com Deutsch | ||
| 21.08. | Azitra regains compliance with NYSE American listing standards | 2 | Investing.com | ||
| 21.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards | 303 | PR Newswire | BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused... ► Artikel lesen | |
| 13.08. | Azitra GAAP EPS of -$0.17 | 1 | Seeking Alpha | ||
| 12.08. | Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates | 175 | PR Newswire | BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused... ► Artikel lesen | |
| 12.08. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Azitra, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,000 | +0,33 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,161 | -10,35 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,524 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| INFLARX | 1,205 | +10,65 % | InflaRx: 2027 - warum die nächsten Studien jetzt zählen | ||
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,191 | -9,29 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| CARDIOL THERAPEUTICS | 0,923 | +0,98 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| GERON | 0,885 | +1,80 % | Geron auf der Stifel Healthcare Conference 2026: RYTELO gewinnt an Dynamik | ||
| IBIO | 0,688 | -1,64 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update | ||
| IMMUNITYBIO | 6,140 | +1,49 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,370 | -1,75 % | Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M | ||
| IMMATICS | 5,840 | +1,74 % | Immatics Announces Third Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,230 | 0,00 % | Cellectar Biosciences GAAP EPS of -$0.46 beats by $0.10 |
AZITRA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,602 Euro und damit +0,17 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.